GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Effective Interest Rate on Debt %

Bioasis Technologies (FRA:107) Effective Interest Rate on Debt % : 39.44% (As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Bioasis Technologies's annualized positive value of Interest Expense for the quarter that ended in Nov. 2022 was €0.62 Mil. Bioasis Technologies's average total debt for the quarter that ended in Nov. 2022 was €1.57 Mil. Therefore, Bioasis Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Nov. 2022 was 39.44%.


Bioasis Technologies Effective Interest Rate on Debt % Historical Data

The historical data trend for Bioasis Technologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Effective Interest Rate on Debt % Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.62 24.51 65.04

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.84 51.91 55.49 49.65 39.44

Competitive Comparison of Bioasis Technologies's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Bioasis Technologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Effective Interest Rate on Debt % falls into.



Bioasis Technologies Effective Interest Rate on Debt % Calculation

Bioasis Technologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Feb. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Feb. 2021 )+Total Debt  (A: Feb. 2022 ))/ count )
=-1  *  -0.453/( (0.074+1.319)/ 2 )
=-1  *  -0.453/0.6965
=65.04 %

where

Total Debt  (A: Feb. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.038 + 0.036
=0.074

Total Debt  (A: Feb. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.279 + 1.04
=1.319

Bioasis Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Nov. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Aug. 2022 )+Total Debt  (Q: Nov. 2022 ))/ count )
=-1  *  -0.62/( (1.531+1.613)/ 2 )
=-1  *  -0.62/1.572
=39.44 %

where

Total Debt  (Q: Aug. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.385 + 1.146
=1.531

Total Debt  (Q: Nov. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.52 + 1.093
=1.613

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Nov. 2022) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Bioasis Technologies  (FRA:107) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Bioasis Technologies Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (FRA:107) Business Description

Industry
Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines